U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 30 results

Status:
US Approved Rx (2012)
First approved in 2012

Class (Stereo):
CHEMICAL (ABSOLUTE)



Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA and by EMA. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. Avanafil selectively inhibits PDE5, thus inhibiting the degradation of cycli...
Status:
US Approved Rx (2019)
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzy...
Status:
US Approved Rx (2012)
First approved in 2003

Class (Stereo):
CHEMICAL (ACHIRAL)



Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by th...
Status:
US Approved Rx (2013)
First approved in 1998

Class (Stereo):
CHEMICAL (ACHIRAL)



Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic...
Status:
US Approved Rx (2017)
First approved in 1961

Class (Stereo):
CHEMICAL (ACHIRAL)



Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used i...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Exisulind (tentative trade name Aptosyn) is an antineoplastic agent, which was originally developed by Cell Pathways. This drug is an inhibitor of phosphodiesterase (PDE) isozymes: PDE5 and PDE4. Inhibition of PDE5 appears to be pharmacologically rel...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Schering published xanthine PDE5 inhibitors with amino substituents in the imidazole 2-position, such as Dasantafil. Dasantafil, also known as SCH-446132, is a PDE5A inhibitor potentially for the treatment of erectile dysfunction. It had been in phas...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Trequinsin is a potent PDE3 inhibitor that inhibits PDE4 and PDE2 at higher concentrations. Trequinsin can block platelet aggregation and also inhibit tissue factor expression in human endothelial cells. Trequinsin can enhance cellular cAMP content, ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Zaprinast is (M&B 22,948; 2-o-propoxy-phenyl-8-azapurin-6-one) is a selective inhibitor of cyclic GMP (cGMP)-dependent phosphodiesterases, with vasodilation activity in a variety of species and tissues. The potency of zaprinast as a vasorelaxant ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Gisadenafil is a phosphodiesterase V inhibitor in clinical development at Pfizer. It had been in phase II clinical trials for the treatment of Benign prostatic hyperplasia; Chronic obstructive pulmonary disease; Erectile dysfunction; Overactive bladd...